Resources to Fight the COVID-19 Pandemic
RCSB PDB is a central resource in the global fight against SARS-CoV-2, the agent of the COVID-19 pandemic. The PDB is the primary repository of atomic structures of viral proteins and nucleic acids, providing the basic understanding that will be needed to discover new therapies and develop vaccines. RCSB PDB provides many resources to access and analyze these structures, and general resources to help understand the mechanisms of the viral life cycle and how they impact health.
These articles provide an introduction to how the biological macromolecules in the PDB are driving research and discovery related to SARS-CoV-2. The science is rapidly expanding. New articles will appear and others will be updated when possible, but they are not intended to offer a comprehensive index.
 | Dexamethasone and Cytokine StormsArticlePreventing too much of a good thing during SARS-CoV-2 infection |
 | Passive Immunization with Convalescent AntibodiesArticlePurified antibodies may be used to treat infection by coronavirus. |
 | The Search for Drugs to Fight COVID-19ArticleMedical researchers are testing previously-discovered antiviral drugs for effectiveness against SARS-CoV-2. |
 | SARS-CoV-2 mRNA VaccineArticleAtomic structures are being used to design effective vaccines against SARS-CoV-2 |
About PDB-101
Researchers around the globe make 3D structures freely available from the Protein Data Bank (PDB) archive. PDB-101 training materials help graduate students, postdoctoral scholars, and researchers use PDB data and RCSB PDB tools. Outreach content demonstrate how PDB data impact fundamental biology, biomedicine, bioengineering/biotechnology, and energy sciences in 3D by a multidisciplinary user community. Education Materials provide lessons and activities for teaching and learning.
PDB-101 is developed by theRCSB PDB.
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.